Revascularisation for Ischaemic Cardiomyopathy
Coronary artery disease is a leading cause of heart failure with reduced ejection fraction. Coronary artery bypass grafting appears to provide clinical benefits such as improvements in quality of life, reductions in readmissions and MI, and favourable effects on long-term mortality; however, there i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2023-08-01
|
| Series: | Interventional Cardiology: Reviews, Research, Resources |
| Online Access: | https://www.icrjournal.com/articleindex/icr.2023.06 |
| _version_ | 1797199964599746560 |
|---|---|
| author | Matthew E Li Kam Wa Saba Z Assar Ajay J Kirtane Divaka Perera |
| author_facet | Matthew E Li Kam Wa Saba Z Assar Ajay J Kirtane Divaka Perera |
| author_sort | Matthew E Li Kam Wa |
| collection | DOAJ |
| description | Coronary artery disease is a leading cause of heart failure with reduced ejection fraction. Coronary artery bypass grafting appears to provide clinical benefits such as improvements in quality of life, reductions in readmissions and MI, and favourable effects on long-term mortality; however, there is a significant short-term procedural risk when left ventricular function is severely impaired, which poses a conundrum for many patients. Could percutaneous coronary intervention provide the same benefits without the hazard of surgery? There have been no randomised studies to support this practice until recently. The REVIVED-BCIS2 trial (NCT01920048) assessed the outcomes of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular dysfunction and stable coronary artery disease. This review examines the trial results in detail, suggests a pathway for investigation and revascularisation in ischaemic cardiomyopathy, and explores some of the remaining unanswered questions. |
| first_indexed | 2024-03-07T17:39:41Z |
| format | Article |
| id | doaj.art-1a9e5bd7b8f24e509f1842ae0bebab1f |
| institution | Directory Open Access Journal |
| issn | 1756-1477 1756-1485 |
| language | English |
| last_indexed | 2024-04-24T07:24:07Z |
| publishDate | 2023-08-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Interventional Cardiology: Reviews, Research, Resources |
| spelling | doaj.art-1a9e5bd7b8f24e509f1842ae0bebab1f2024-04-20T16:03:34ZengRadcliffe Medical MediaInterventional Cardiology: Reviews, Research, Resources1756-14771756-14852023-08-011810.15420/icr.2023.06Revascularisation for Ischaemic CardiomyopathyMatthew E Li Kam Wa0Saba Z Assar1Ajay J Kirtane2Divaka Perera3Coronary Research Group, British Heart Foundation Centre of Research Excellence, King’s College London, London, UK2. Division of Cardiology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, USDivision of Cardiology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, NY, US; Cardiovascular Research Foundation, New York, NY, USCoronary Research Group, British Heart Foundation Centre of Research Excellence, King’s College London, London, UK; Cardiovascular Division, Guy’s and St Thomas’ NHS Foundation Trust, London, UKCoronary artery disease is a leading cause of heart failure with reduced ejection fraction. Coronary artery bypass grafting appears to provide clinical benefits such as improvements in quality of life, reductions in readmissions and MI, and favourable effects on long-term mortality; however, there is a significant short-term procedural risk when left ventricular function is severely impaired, which poses a conundrum for many patients. Could percutaneous coronary intervention provide the same benefits without the hazard of surgery? There have been no randomised studies to support this practice until recently. The REVIVED-BCIS2 trial (NCT01920048) assessed the outcomes of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular dysfunction and stable coronary artery disease. This review examines the trial results in detail, suggests a pathway for investigation and revascularisation in ischaemic cardiomyopathy, and explores some of the remaining unanswered questions.https://www.icrjournal.com/articleindex/icr.2023.06 |
| spellingShingle | Matthew E Li Kam Wa Saba Z Assar Ajay J Kirtane Divaka Perera Revascularisation for Ischaemic Cardiomyopathy Interventional Cardiology: Reviews, Research, Resources |
| title | Revascularisation for Ischaemic Cardiomyopathy |
| title_full | Revascularisation for Ischaemic Cardiomyopathy |
| title_fullStr | Revascularisation for Ischaemic Cardiomyopathy |
| title_full_unstemmed | Revascularisation for Ischaemic Cardiomyopathy |
| title_short | Revascularisation for Ischaemic Cardiomyopathy |
| title_sort | revascularisation for ischaemic cardiomyopathy |
| url | https://www.icrjournal.com/articleindex/icr.2023.06 |
| work_keys_str_mv | AT matthewelikamwa revascularisationforischaemiccardiomyopathy AT sabazassar revascularisationforischaemiccardiomyopathy AT ajayjkirtane revascularisationforischaemiccardiomyopathy AT divakaperera revascularisationforischaemiccardiomyopathy |